← Back to Search

Other

Active Treatment (HB-01) for Panic Disorder

Phase 2
Waitlist Available
Led By David Walling
Research Sponsored by Honeybrains Biotech LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 2, week 4, week 8 and week 12

Summary

This trial is testing a new treatment called HB-1 to see if it helps adults aged 18 to 60 who have panic disorder. The study will determine its safety and effectiveness. About 80 patients will participate, and they will be treated for a few months.

Eligible Conditions
  • Panic Disorder

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 2, week 4, week 8 and week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 2, week 4, week 8 and week 12 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Clinical Global Impression-Severity Scale (CGI-I)
Change in Panic Disorder Symptom Severity Scale (PDSS)
Incidence of Treatment-Emergent Adverse Events
+1 more

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active Treatment (HB-01)Active Control1 Intervention
Approximately 40 patients will receive HB-01 active study drug.
Group II: Placebo TreatmentPlacebo Group1 Intervention
Approximately 40 patients will receive a matched placebo.

Find a Location

Who is running the clinical trial?

Honeybrains Biotech LLCLead Sponsor
1 Previous Clinical Trials
240 Total Patients Enrolled
1 Trials studying Panic Disorder
240 Patients Enrolled for Panic Disorder
Cognitive Research CorporationIndustry Sponsor
24 Previous Clinical Trials
2,302 Total Patients Enrolled
David WallingPrincipal InvestigatorCollaborative NeuroScience Research, Garden Grove, CA
1 Previous Clinical Trials
69 Total Patients Enrolled
~23 spots leftby Nov 2025